Supernus Pharmaceuticals Inc (NASDAQ:SUPN) saw unusually large options trading on Wednesday. Stock traders bought 1,346 put options on the stock. This represents an increase of approximately 456% compared to the average daily volume of 242 put options.

Several research firms recently commented on SUPN. B. Riley dropped their price target on Supernus Pharmaceuticals from $68.00 to $65.00 and set a “buy” rating for the company in a research report on Monday, November 12th. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 8th. Cantor Fitzgerald set a $57.00 price target on Supernus Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 7th. BidaskClub lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 7th. Finally, ValuEngine lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 6th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Supernus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $56.00.

Several large investors have recently made changes to their positions in the business. BlackRock Inc. boosted its position in shares of Supernus Pharmaceuticals by 4.1% during the third quarter. BlackRock Inc. now owns 8,003,001 shares of the specialty pharmaceutical company’s stock valued at $402,951,000 after buying an additional 312,332 shares during the period. FMR LLC boosted its position in shares of Supernus Pharmaceuticals by 151.9% during the third quarter. FMR LLC now owns 2,371,321 shares of the specialty pharmaceutical company’s stock valued at $119,396,000 after buying an additional 1,430,021 shares during the period. Glenmede Trust Co. NA boosted its position in shares of Supernus Pharmaceuticals by 52.2% during the third quarter. Glenmede Trust Co. NA now owns 993,483 shares of the specialty pharmaceutical company’s stock valued at $50,020,000 after buying an additional 340,677 shares during the period. Wells Fargo & Company MN boosted its position in shares of Supernus Pharmaceuticals by 6.8% during the second quarter. Wells Fargo & Company MN now owns 957,210 shares of the specialty pharmaceutical company’s stock valued at $57,290,000 after buying an additional 61,100 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Supernus Pharmaceuticals by 191.3% during the second quarter. Renaissance Technologies LLC now owns 884,690 shares of the specialty pharmaceutical company’s stock valued at $52,949,000 after buying an additional 580,990 shares during the period. Institutional investors and hedge funds own 97.83% of the company’s stock.

SUPN opened at $42.78 on Thursday. The stock has a market capitalization of $2.21 billion, a P/E ratio of 33.95 and a beta of 0.92. Supernus Pharmaceuticals has a 12 month low of $34.90 and a 12 month high of $61.25. The company has a quick ratio of 2.65, a current ratio of 2.82 and a debt-to-equity ratio of 0.77.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.09. Supernus Pharmaceuticals had a return on equity of 30.30% and a net margin of 25.89%. The business had revenue of $102.99 million during the quarter, compared to analyst estimates of $100.75 million. During the same quarter in the previous year, the business earned $0.29 earnings per share. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. Analysts anticipate that Supernus Pharmaceuticals will post 1.87 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Supernus Pharmaceuticals Sees Unusually High Options Volume (SUPN)” was reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/11/22/supernus-pharmaceuticals-sees-unusually-high-options-volume-supn.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Further Reading: Find a Trading Strategy That Works

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.